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THE 6th EXPERT MEETING ON THERAPEUTIC MSCs FOR IMMUNE MODULATION 
REGENSBURG, GERMANY. OCTOBER 27 – 28, 2016 
 
Thursday 27 October 
Meeting Venue 
Brücksaal im Historischen Salzstadl 
(directly at the “Steinerne Brücke”)  
Weiße-Lamm-Gasse 1, 93047 Regensburg  
Phone: +49 (0)941 5071415 
 
The "Salzstadel" (salt barn) dates from 1616 and is a 
reminder of the salt trade from which Regensburg has 
housed restaurants, several shops and even rentable 
rooms. The building now also houses the Regensburg 
UNESCO World Heritage visitor center. 
8:30 – onwards registration & view company exhibitions 
8:55 MiSOT opening address. 
 Marc Dahlke, Regensburg, Germany. 
Session 1. Mechanistic insights into MSC therapies 
09:15 What do we really know about MSC therapy? 
 Martin Hoogduijn, Rotterdam, The Netherlands. 
09:45 Molecular pathways affected by MSC in a model of non-alcoholic steatohepatitis. 
 Bruno Christ, Leipzig, Germany 
10:00 How mechanistic studies on MSCs inform design of human clinical trials - The fitness 
paradigm. 
 Jacques Galipeau, Madison, Wisconsin, USA. 
10:30 Inflammatory conditions dictate the immunomodulatory effect of MSC on B cell 
function. 
 Marcella Franquesa, Badalona, Spain. 








Session 2. MSC for solid organ transplantation 
11:35 3D MSCs constructs in models of chronic liver failure. 
 Murat Shagidulin, Moscow, Russia. 
11:50 What do we learn from MSC treatment in clinical kidney transplantation? 
 Marlies Reinders, Leiden, The Netherlands. 
12:20 MSC after deceased donor liver transplantation: a phase I/II study of the University of 
Liege. 
 Olivier Detry, Liège, Belgium. 
12:50 Safety and Tolerance of Immunomodulating Therapy with Donor-specific 
Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation. 
 Steffen Hartleif, Tübingen, Germany. 
13:05 Mesenchymal stromal cells to promote tolerance in kidney transplantation: from mice 
to men and back. 
 Giuseppe Remuzzi, Bergamo, Italy. 
13:35 Lunch 
 
Session 3. MSC for inflammatory and immunological disorders 
14:35 Cellular Immunotherapy for Severe Sepsis: the CISS Trial. 
 Claudia Dos Santos, Ottawa, Canada.  
15:05 Katarina Le Blanc, Stockholm, Sweden. 
15:35 MSC: a new route in the road map of therapies for inflammatory bowel diseases. 
 Rachele Ciccocioppo, Pavia, Italy. 
16:05 UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit 
the inflammatory response of stimulated T cells. 
 Marta Monguió-Tortajada, Badalona, Spain. 
16:20 Harnessing Mesenchymal Stromal Cells for Immune Modulatory Treatment. 
 Wim Fibbe, Leiden, The Netherlands. 
 
19:00 Networking Dinner 
  
 Haus Heuport 
 Domplatz 7, 93047 Regensburg 










Friday 28 October 
 
Session 4. Corporate Session: Bringing MSC-based technologies to market 
9:00 Generation of polyclonal Tregs with superior expansion potential and enhanced 
Th1 suppression via MAPC co-culture. 
 Samantha Stubblefield, Regenerative Medicine Scientist, Athersys Inc. 
9:20 From CD362 to ORBCEL: the rapid development of an allogeneic stromal cell 
immunotherapy 
 Stephen Elliman, CSO, Orbsen Therapeutics. 
9:40 Case Study review on large scale manufacturing of MSCs. 
 Amel Tounsi, Project & Development Manager, MaSTherCell. 
10:00 Potential use of adipose mesenchymal stem cells in sepsis: The SEPCELL trial 
 Eleuterio Lombardo, Scientific Director, TiGenix SAU. 
10:20 Addressing Challenges in ATMP Manufacture. 
 Layka Abbasi, Cell processing Specialist, Terumo BCT. 
10:40 Alpha 1 anti-trypsin expressing mesenchymal stem cells suppress type 1 
diabetes development in NOD mice 




Session 5. MSC for tissue protection 
11:15 Impact of timing administration of mesenchymal stromal cells following renal 
ischemia/reperfusion in rats. 
 Pauline Erpicum, Liège, Belgium.  
11:45 MSC in immune-mediated liver disease. 
 Philip Newsome, Birmingham, UK. 
12:15 Normothermic Organ Perfusion: Opportunities and Challenges. 
 Rutger Ploeg, Oxford, UK. 
12:45 Administering MSCs to an isolated organ prior to transplantation. 
 Cyril Moers, Groningen, The Netherlands. 
13:15 – Lunch plus closing remarks 
 
